Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Cello Group LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +2.00p +1.98% 103.00p 302,720 16:07:07
Bid Price Offer Price High Price Low Price Open Price
101.00p 105.00p 103.00p 99.50p 101.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 169.29 5.82 4.09 25.2 107.9

Cello (CLL) Latest News

More Cello News
Cello Takeover Rumours

Cello (CLL) Share Charts

1 Year Cello Chart

1 Year Cello Chart

1 Month Cello Chart

1 Month Cello Chart

Intraday Cello Chart

Intraday Cello Chart

Cello (CLL) Discussions and Chat

Cello Forums and Chat

Date Time Title Posts
26/11/201811:07Cello - solid prospects1,005
29/1/201516:56CELLO GROUP?9
12/1/200516:17Cello or EQI?-

Add a New Thread

Cello (CLL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-12-10 17:04:39101.0042,93343,362.33O
2018-12-10 16:07:45100.5042,93343,147.67O
2018-12-10 16:07:27100.5042,93343,147.67O
2018-12-10 16:07:27105.0042,93345,079.65O
2018-12-10 16:06:59105.0042,93345,079.65O
View all Cello trades in real-time

Cello (CLL) Top Chat Posts

Cello Daily Update: Cello Group is listed in the Media sector of the London Stock Exchange with ticker CLL. The last closing price for Cello was 101p.
Cello Group has a 4 week average price of 95.70p and a 12 week average price of 95.70p.
The 1 year high share price is 140.50p while the 1 year low share price is currently 95.70p.
There are currently 104,711,241 shares in issue and the average daily traded volume is 76,479 shares. The market capitalisation of Cello Group is £107,852,578.23.
qs99: Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla
davebowler: FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition.
zipstuck: The oversubscribed placing underpins the share price and there is all to play for in 2017
davebowler: Price: 100.0p Target Price: 132.0p Cello has confirmed the Group delivered an encouraging trading performance in 2016 and 2017 begins with good momentum from existing and new clients. Most importantly for our buy case, there has been an ‘excellent performance’ from Cello’s growing suite of software-enabled products. We make no changes to our forecasts and continue to believe the share price significantly undervalues the technologies Cello has developed, most notably Pulsar its social media analytics tool which we believe is in the price for free.
davebowler: Finncap; Price: 106.0p Target Price: 132p Cello has an overlooked and potentially significantly undervalued asset that is now out of development phase. Cello Pulsar is a social media analytics tool that has significant points of difference to the competition. In the right hands, social media data can inform, direct and optimise marketing campaigns but to date its usage has been constrained by early-stage science and customer unfamiliarity. Competitors in this area have individually raised nearly half of Cello's market cap, emphasising Pulsar’s potential to add very material value to the share price. We initiate at Buy.
qs9: nice IMO to see directors taking advantage of recent share price weakness...
hpcg: I think its a bit chicken and egg with regards to liquidity / spread; its thinly traded which puts people off. If they participated then there would be more liquidity! However I'm speculating as to the motives of others, and it could just be that investors want to see more prolonged evidence of progress. If the company does the business the share price will as well.
jeff h: Singer Capital Markets is initiating coverage of market research and consulting group Cello with a positive recommendation, saying that most of the company's earn out obligations from previous takeovers are behind it and the company is in a position again to expand through acquisition. The company's recent interim results demonstrated a return to positive growth despite extreme near term headwinds in the public sector, which Singer rates as "an exceptionally strong performance in this context." The broker thinks there are three main reasons to buy the shares. First is the aforementioned revenue growth. "Acquisitions are back on the agenda and will enhance growth. Cello's biggest business segment, Healthcare, is driving growth and international expansion offsetting the short term public sector headwind," the broker said. Cello chief executive Mark Scott told Sharecast earlier this week that the company "will buy again, probably in America" and that the plan is to double the size of Cello in the next two or three years. The second reason to buy cited by Singer is the company's strong positions in market research and healthcare. These are "scarce assets in a consolidating market." The broker also believes the shares are undervalued because the earnings are in the low part of the cycle. Compared to the valuation of its peers, the stock is cheap, and Singer thinks it is also undervalued on a sum of the parts (SOTP) basis and as a prospective takeover target. The stock trades on 6.6 times projected earnings per share for 2010 while the ratio of enterprise value to earnings before interest, tax, depreciation and amortisation is just 4.6. "This is clearly low," the broker argues. "If the share price does not recover then it is possible that Cello could become a target, given the scarcity value of its two operating units. We use a blended SOTP and peer based valuation to derive our 12 month target price, which we set at 71p, indicating over 50% upside," the broker concluded
glasshalfull: Signs of life in the CLL share price in the last few sessions. If recent years are anything to go by then there is a very strong chance of a trading update anytime now. Trading statements released on the following dates:- 3rd July 2009 4th July 2008 12th July 2007 3rd July 2006 2010 market updates 19th January 2010 - pre-close trading update indicated that there were signs of improvement in markets. 16th March 2010 preliminary results confirmed improvement, "Cello has strong revenue pipelines in Research and Consulting and Tangible has also seen a marked increase in levels of new business activity." 17th May 2010 - AGM statement noted "The Group has therefore performed strongly during the first quarter of 2010. While there remains economic uncertainty, we are growing in confidence about the Group's performance." So, given that guidance in 2010 has been of improving markets and strong performance (so far) I'm hopeful that CLL will be in line with market forecasts at the very least....and there's always a possibility that they may be ahead. Worth reiterating m my earlier post - 364 Altium snippet on AGM update "...we continue to view the group's stock as substantially undervalued and would cite: (a) the quality of its underlying operating assets, (b) robust financials (debt well within long-term facilities of £17m), and (c) earnings growth potential as a recovery in research and marketing spend plays through a scaleable cost base, as key attractions. We are nudging up our target price from 46p to 49p (an undemanding 7x FY 2010E PER / c.48% upside) to reflect the encouraging momentum highlighted above and reiterate our BUY recommendation." Regards, GHF
glasshalfull: Well I disagree GCI :-) I've been nibbling away and have bought a few CLL since results which I expect to represent the nadir of the share price underperformance. I had researched and was a holder of CLL back in 2006 and discovered that I still had a few (dormant account), so only recently got up to speed on developments since. My interest was rekindled having carried out comprehensive research on Adventis (ATG) a marketing services company - see link below - and I noticed that both ATG and CLL had failed to enjoy the shareprice recovery that many of their peers had. I've started a write-up on CLL and will post when complete. Regards GHF
Cello share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181211 04:41:04